Skip to content

LSD research published in 2018

32 studies whose primary subject is LSD were published in 2018, down from 44 in 2017. Newest first. Back to the LSD overview

Studies

História social do LSD no Brasil: os primeiros usos medicinais e o começo da repressão

December 11, 2018 Júlio Delmanto Franklin de Matos

\n Depois de apresentar as origens históricas da contracultura, no Brasil e nos Estados Unidos, e contextualizar um pouco das relações entre os integrantes destes movimentos e o uso de drogas, sobretudo maconha e ácido lisérgico, esse trabalho traça, através principalmente da análise de trajetórias individuais que se cruzam de uma forma ou de outra, uma história social da chegada do LSD ao...

DOI: 10.11606/t.8.2018.tde-11122018-161707 (opens in new tab) Full text (opens in new tab) Dictatorship Possession linguistics Counterculture Drug trafficking +3

The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial

Psychopharmacology November 26, 2018 Steliana Yanakieva, Naya Polychroni, Neiloufar Family et al. 169 citations

RATIONALE: Previous research demonstrating that lysergic acid diethylamide (LSD) produces alterations in time perception has implications for its impact on conscious states and a range of psychological functions that necessitate precise interval timing. However, interpretation of this research is hindered by methodological limitations and an inability to dissociate direct neurochemical effects...

RETRACTED: Long-term systemic treatment with lysergic acid diethylamide causes retinal damage in CD1 mice

Human & Experimental Toxicology November 25, 2018 H. Jiang, H. Xu Retracted

As a classical hallucinogen with high potential for abuse, lysergic acid diethylamide (LSD) can cause long-lasting abnormalities in retina, but little is known about the exact mechanism. This study was to investigate effects of long-term systemic treatment of LSD at low dose on retinal damage and understand the underlying mechanisms. CD1 mice were treated intraperitoneally with 0.1 mg/kg or 0.2...

Role of mGlu2 in the 5-HT2A receptor-dependent antipsychotic activity of clozapine in mice.

Psychopharmacology November 2018 Kelsey S. Hideshima, Ashkhan Hojati, Justin M. Saunders et al.

Serotonin 5-HT2A and metabotropic glutamate 2 (mGlu2) are neurotransmitter G protein-coupled receptors (GPCRs) involved in the signaling mechanisms underlying psychosis and schizophrenia treatment. Previous findings in mGlu2 knockout (KO) mice suggested that mGlu2 is necessary for head-twitch behavior, a rodent phenotype characteristic of hallucinogenic 5-HT2A receptor agonists. However, the...

Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor

Elife October 25, 2018 Katrin H. Preller, Joshua B. Burt, Jie Lisa Ji et al. 416 citations

Background: Lysergic acid diethylamide (LSD) has agonist activity at various serotonin (5-HT) and dopamine receptors. Despite the therapeutic and scientific interest in LSD, specific receptor contributions to its neurobiological effects remain unknown. Methods: We therefore conducted a double-blind, randomized, counterbalanced, cross-over studyduring which 24 healthy human participants received...

DOI: 10.7554/elife.35082 (opens in new tab) Serotonin Ketanserin Neuropharmacology Agonist +2

Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions

Current Molecular Pharmacology October 15, 2018 Ricardo Jorge Dinis-Oliveira, Carolina Lança Pereira, Diana Dias Da Silva 101 citations

Background:Mescaline (3,4,5-trimethoxyphenethylamine), mainly found in the Peyote cactus (Lophophora williamsii), is one of the oldest known hallucinogenic agents that influence human and animal behavior, but its psychoactive mechanisms remain poorly understood.Objective:This article aims to fully review pharmacokinetics and pharmacodynamics of mescaline, focusing on the in vivo and in vitro...

Increased use of illicit drugs in a Dutch cluster headache population

Cephalalgia October 5, 2018 Ilse F. de Coo, Willemijn C. Naber, Leopoldine A. Wilbrink et al. 47 citations

Introduction Many patients with cluster headache report use of illicit drugs. We systematically assessed the use of illicit drugs and their effects in a well-defined Dutch cluster headache population. Methods In this cross-sectional explorative study, 756 people with cluster headache received a questionnaire on lifetime use and perceived effects of illicit drugs. Results were compared with age...

“Eye Dropping”—A Case Report of Transconjunctival Lysergic Acid Diethylamide Drug Abuse

Cornea October 1, 2018 Danielle Lo, Lucy Cobbs, Michael Chua et al. 4 citations

Purpose: To report a case of bilateral toxic corneal and conjunctival epitheliopathy secondary to administration of filter paper impregnated with lysergic acid diethylamide (LSD) in the inferior conjunctival fornices. Methods: This is a single case report of an 18-year-old man who presented to the emergency department with acute, bilateral eye pain and redness of 24 hours. The patient admitted...

Whole-Brain Multimodal Neuroimaging Model Using Serotonin Receptor Maps Explains Non-linear Functional Effects of LSD.

Current Biology September 27, 2018 Gustavo Deco, Josephine Cruzat, Joana Cabral et al. 246 citations

Understanding the underlying mechanisms of the human brain in health and disease will require models with necessary and sufficient details to explain how function emerges from the underlying anatomy and is shaped by neuromodulation. Here, we provide such a detailed causal explanation using a whole-brain model integrating multimodal imaging in healthy human participants undergoing manipulation...

DOI: 10.1016/j.cub.2018.07.083 (opens in new tab) LSD Brain Effects Serotonin receptors Neuropharmacology

Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics.

Journal of experimental neuroscience September 19, 2018 David E. Olson

Neural plasticity-the ability to change and adapt in response to stimuli-is an essential aspect of healthy brain function and, in principle, can be harnessed to promote recovery from a wide variety of brain disorders. Many neuropsychiatric diseases including mood, anxiety, and substance use disorders arise from an inability to weaken and/or strengthen pathologic and beneficial circuits,...

Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016

Journal of Psychopharmacology September 5, 2018 James B. Leonard, Bruce D. Anderson, Wendy Klein‐schwartz 85 citations

Background: Lysergic acid diethylamide (LSD) and psilocybin are serotonergic hallucinogens that are used primarily for recreational abuse. Small studies evaluated the efficacy of LSD and psilocybin for several psychiatric conditions. There are limited safety or toxicity data for either of these substances, especially in large populations. Methods: This was a retrospective analysis of...

DOI: 10.1177/0269881118793086 (opens in new tab) Psilocybin Hallucinogen Mushroom poisoning Poison control

LSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice

Frontiers in Pharmacology August 31, 2018 Kenneth Alper, Bin Dong, Relish Shah et al. 37 citations

There is a substantive clinical literature on classical hallucinogens, most commonly lysergic acid diethylamide (LSD) for the treatment of alcohol use disorder. However, there has been no published research on the effect of LSD on alcohol consumption in animals. This study evaluated the effect of LSD in mice using a two-bottle choice alcohol drinking paradigm. Adult male C57BL/6J mice were...

Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews

Expert Review of Clinical Pharmacology August 13, 2018 Rafael G. Dos Santos, José Carlos Bouso, Miguel Ángel Alcázar‐córcoles et al. 231 citations

Mood, anxiety, and substance-use disorders are among the most prevalent psychiatric disorders in the population. Although several pharmacological treatments are available, they are not effective for a significant proportion of patients and are associated with several adverse reactions. Therefore, new treatments should be explored. Recent studies suggest that serotonergic...

Psychedelics and psychotherapy in Canada: Humphry Osmond and Aldous Huxley.

History of psychology August 1, 2018 Erika Dyck, Patrick Farrell 21 citations

The decade of the 1950s is well known among historians of psychiatry for the unprecedented shift toward psychopharmacological solutions to mental health problems. More psychiatric medications were introduced than ever before or since (Healy, 2002). While psychiatric researchers later credited these drugs, in part, for controlling psychotic, depressive, and anxious symptoms-and subsequently for...

“Ayahuasca turned on my mind’s eye”: Enhanced visual imagery after ayahuasca intake in a man with “blind imagination” (aphantasia)

Journal of Psychedelic Studies July 25, 2018 Rafael G. Dos Santos, Scotty Enyart, José Carlos Bouso et al. 18 citations

Aphantasia ("blind imagination") is a poorly described condition with an uncertain etiology, characterized by reduced or lack of voluntary visual imagery. Preliminary evidence in humans suggests that hallucinogenic or psychedelic drugs that act as agonists of cortical 5-HT2A receptors [lysergic acid diethylamide, psilocybin, and dimethyltryptamine (DMT)] enhance visual imagery. Interview and...

Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine

ACS Chemical Neuroscience July 12, 2018 Lee E. Dunlap, Anne M. Andrews, David E. Olson 105 citations

Better known as "ecstasy", 3,4-methylenedioxymethamphetamine (MDMA) is a small molecule that has played a prominent role in defining the ethos of today's teenagers and young adults, much like lysergic acid diethylamide (LSD) did in the 1960s. Though MDMA possesses structural similarities to compounds like amphetamine and mescaline, it produces subjective effects that are unlike any of the...

Psychedelics and Personality

ACS Chemical Neuroscience June 4, 2018 Marc Aixalà, Rafael G. Dos Santos, Jaime E. C. Hallak et al. 14 citations

In the past decade, an increasing number of clinical trials are reporting evidence that psychedelics or serotonergic hallucinogens (such as lysergic acid diethylamide, psilocybin, and ayahuasca/dimethyltryptamine) could be effective in the treatment of mood, anxiety, and substance use disorders. The mechanisms responsible for these effects are not fully understood but seem to involve changes in...

Lysergic Acid Diethylamide and Psilocybin for the Management of Patients with Persistent Pain: a Potential Role?

Pain Management May 1, 2018 Andy Whelan, Mark I Johnson 51 citations

Recently, there has been interest in lysergic acid diethylamide (LSD) and psilocybin for depression, anxiety and fear of death in terminal illness. The aim of this review is to discuss the potential use of LSD and psilocybin for patients with persistent pain. LSD and psilocybin are 5-hydroxytryptamine receptor agonists and may interact with nociceptive and antinociceptive processing. Tentative...

DOI: 10.2217/pmt-2017-0068 (opens in new tab) Full text (opens in new tab) Psychedelics Clinical research Chronic pain Mental health +1

Using in vitro norepinephrine transporter (NET) inhibition and 5‐HT 2 receptor binding data to predict psychoactive doses of novel psychoactive substances in humans

The FASEB Journal April 1, 2018 Matthias E. Liechti, Dino Luethi

Objective Novel psychoactive substances (NPS) or “bath salts” are increasingly sold over the Internet and used as substitutes for classic recreational substances. Previous studies showed that classic amphetamine‐type stimulants most potently act on the norepinephrine (NE) compared to the dopamine (DA) and serotonin (5‐HT) system and NE activation correlated with the subjective effects across...

Synesthetic hallucinations induced by psychedelic drugs in a congenitally blind man.

Consciousness and Cognition April 1, 2018 Sara Dell'Erba, David J Brown, Michael J. Proulx 11 citations

This case report offers rare insights into crossmodal responses to psychedelic drug use in a congenitally blind (CB) individual as a form of synthetic synesthesia. BP's personal experience provides us with a unique report on the psychological and sensory alterations induced by hallucinogenic drugs, including an account of the absence of visual hallucinations, and a compelling look at the...